Merck & Co.: Evaluating a Drug Licensing Opportunity

是 否 +2 论坛币

k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群

赵安豆老师微信：zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

立即领取

感谢您参与论坛问题回答

经管之家送您两个论坛币！

+2 论坛币

【案例名称】Merck & Co.: Evaluating a Drug Licensing Opportunity

【作者】Richard S. Ruback, David Krieger

【页数】6

【格式】PDF

【语言】英语

【出版日期】2000年10月30日

【修订日期】2003年3月25日

【学科】金融 (Finance)

【案例编号】201023-PDF-ENG

【来源】HBS Premier Case Collection

【网页】http://cb.hbsp.harvard.edu/cb/product/201023-PDF-ENG

【简介】

This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of the three phases of the review process, the revenues if approved, and the probability of various outcomes. It includes an introduction to decision tree analysis and valuation.

【学习目标】

To explore decision tree analysis and risk/reward modeling. The primary pedagogical objective is to learn how to build and use decision trees.

【涉及课题】

Capital budgeting; Decision trees; Investments; Present value; Valuation

【背景】

• Industry: Pharmaceuticals
• Company Revenue: $33 billion revenues
• Event Year Begin: 1999
• Event Year End: 1999
  

【下载】

http://www.mbabbs.com/thread-1377-1-1.html

扫码加我 拉你入群

请注明：姓名-公司-职位

以便审核进群资格，未注明则拒绝

分享0 收藏0 回帖

关键词：Opportunity Evaluating Valuating Licensing Merck valuation compound clinical product before